Why the study?
Does labetalol alter lipoprotein metabolism in patients with mild hypertension?
Does labetalol alter lipoprotein metabolism in patients with mild hypertension?
Labetalol appears to have a neutral effect on lipid profiles and lipoprotein metabolism in patients with mild hypertension.
Answers are grounded in this paper and cite their sources.
Labetalol shows neutral lipoprotein effects in mild hypertension; hypothesis-generating and requires randomized confirmation.
The effects of labetalol on serum lipoproteins, the intravenous fat tolerance test (IVFTT) and lipoprotein lipase (LPL) and hepatic lipase (HL) activities were studied in 16 patients with mild hypertension before and after 6 months of therapy. Most patients were found to be normotensive on 200 mg labetalol/day. Before therapy the mean concentration of serum TG was 0.75 +/- 0.21 (SD) mmol/l, of total cholesterol 5.41 +/- 1.25 mmol/l and of HDL cholesterol 1.67 +/- 0.61 mmol/l. After labetalol no significant changes were found in the concentrations of TG and cholesterol in the VLDL, LDL and HDL fractions. The mean values for the IVFTT and for LPL and HL activities were in the normal range and remained unchanged during therapy.
No takes yet. Share an insight, caveat, or question.
Hylander et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: